Adiposs SA

Adiposs SA is a clinical-stage, top 100 Swiss life science start-up developing transformative imaging products and technologies.
20 million people get diagnosed with cancer and a staggering 10 million cancer patients die every year. This because 2 out of 3 cancer patients do not respond to therapy. Nobody knows who will respond.
Adiposs is developing the first and only contrast agent for brown fat in cancer patients called ImageBAT®. It is an add-on product to the standard-of-care CT / PET-CT cancer scan available in virtually all hospitals worldwide. ImageBAT® predicts the response to cancer therapy and enables personalised therapy with improved quality of life and survival on a global scale.